CL
Therapeutic Areas
Estrella Immunopharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EB103 | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (NHL) | Phase I/II |
| EB104 | B-cell Malignancies (CD19/CD22) | Discovery/Preclinical |
| EB103 + Oncolytic Virus | Multiple Solid Tumors | Discovery/Preclinical |
| EB201 | Systemic Lupus Erythematosus (SLE) | Discovery |